By Fineline Cube 
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) announced that its wholly‑owned subsidiary Minhai Biotechnology has co‑founded the Beijing Key Laboratory of Synthetic Immunology and Vaccine Intelligent Manufacturing with the Institute of Microbiology of the Chinese Academy of Sciences (CAS), Xinzhi Bio, and Liaoning Cheng Da Biotechnology. The laboratory aims to achieve breakthroughs in antigen design, adjuvant development, and intelligent vaccine production to establish a world‑leading rapid response system.
Laboratory Overview
| Item | Detail |
|---|---|
| Name | Beijing Key Laboratory of Synthetic Immunology and Vaccine Intelligent Manufacturing |
| Host | Institute of Microbiology, Chinese Academy of Sciences (CAS) |
| Co‑Founders | Minhai Biotechnology (Kangtai Biological 300601.SZ subsidiary), Xinzhi Bio, Liaoning Cheng Da Biotechnology |
| Strategic Focus | Synthetic immunology and intelligent vaccine manufacturing |
| Core Objectives | Breakthroughs in antigen design, adjuvants, delivery systems, quality control; overcome multivalent vaccine bottlenecks |
Core Research Directions
1. AI‑Assisted Precision Immunogen Design
- Implements closed‑loop research from immune mechanisms to functional epitopes
- Accelerates rational vaccine design using machine learning
2. Variant Monitoring + AI Structural Vaccinology
- Addresses rapid pathogen mutation and diverse serotypes
- Aims for “one vaccine for multiple diseases” (e.g., RSV‑hMPV combined vaccine)
3. Manufacturing Process Breakthroughs
- Overcomes key technical bottlenecks in new vaccine production
- Achieves significant scaling of existing production capacity
- Enables rapid response to emerging infectious diseases
Strategic Significance
Domestic Vaccine Innovation: The laboratory positions China at the forefront of next‑generation vaccine technology, reducing reliance on imported platforms.
Industrial Collaboration: CAS provides basic research excellence; Kangtai contributes clinical development and manufacturing scale‑up; private partners bring commercialization expertise.
Market Impact: Successful development could unlock ¥50‑80 billion in annual vaccine market value by 2030, with Kangtai capturing 15‑20% market share through first‑mover advantages.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the laboratory’s research outcomes, timeline to commercialization, and market impact. Actual results may differ materially due to research challenges, regulatory hurdles, and competitive dynamics.-Fineline Info & Tech